2025 Q4 -tulosraportti
57 päivää sitten
‧29 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 581 | - | - | ||
| 496 | - | - | ||
| 771 | - | - | ||
| 415 | - | - | ||
| 72 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 19.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 13.5.2025 | ||
2024 Q4 -tulosraportti 21.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·9 t sittenHave you seen the news now folks, this must surely be gold that can make the stock rise considerably?
·7 t sittenYou must justify why it is a "gold" news because then we haven't read the same news?·7 t sittendo you see that I put a question mark at the end there, I am wondering then if this was good news just to express myself a bit more clearly....
·3 päivää sittenAfter a couple of turbulent years in the biotech sector, Cantargia is now in a position where the risk/reward ratio looks unusually attractive. Here are the three supporting pillars of the current bull case: 1. Financial stability and "Proof of Concept" The sale of the CAN10 program to Otsuka Pharmaceutical is the most important event in the company's recent history. It has two crucial effects: Validation: A global player like Otsuka does not buy into the platform without extremely thorough due diligence. This removes a large part of the technical uncertainty surrounding the IL1RAP platform. Cash Runway: With cash reserves extending into 2028, the company is protected against the aggressive, dilutive emissions that otherwise plague the sector. This gives management peace of mind to negotiate from a position of strength. 2. Nadunolimab: Strong data in an "Unmet Need" The main asset, nadunolimab, has delivered convincing results in difficult indications such as pancreatic cancer (PDAC). Data shows an extension of survival (OS) in patients with high IL1RAP expression, which enables a "precision medicine" approach. With FDA’s Fast Track designation, the path to market is shortened, and the company is now facing the crucial pivotal studies. 3. Technical setup and pricing Technically, the stock has consolidated after the falls of recent years. We currently see a positive divergence in RSI, which often indicates that selling pressure is exhausted, and the bottom has been formed. The market capitalization currently primarily reflects the value of the agreement with Otsuka, which means that the market almost prices their oncology pipeline (nadunolimab) at zero. This provides a significant "margin of safety". Conclusion: The big trigger in 2026 will be a potential partnership agreement for nadunolimab. If Cantargia can land an agreement of the same magnitude as CAN10, but for the oncology leg, a significant re-pricing of the stock is set to occur. Remember as always: Biotech requires patience and risk appetite. DYOR.·2 päivää sitten · MuokattuThe many irrelevant small comments - see e.g. below - unfortunately cause important posts like the one above to quickly move down the list and disappear. This absolutely does not do any good for either the stock or the debate. Self-discipline is requested so that this debate page on Shareville does not develop into Facebook, as many other pages have done. If you want to "small-talk" with someone or comment without it being relevant to others, there is a special option on Shareville where you can communicate directly with another person: You can go to the person's profile, look under activity, find a trade, and send a comment below it. This naturally requires that the person has an open portfolio where he/she conducts trades.
·2 päivää sittenYes, I can well see that it must be a huge pro lem with the ENORMOUS activity. It's practically once every month that a post appears.
·10.4.So I became a shareholder in Cantargia.·8 t sittenPossibility that we move towards 6,- in the near future, but one never knows...it is after all Cantargia.·17 min sittenThat's not how I interpret it. We must wait to hear exactly what they present.
·1.4.Do they reach their goals or do they just maintain the projects to get paid?·2 päivää sittenAs usual, only green for a single day, only to then quickly move back towards 4,-.
·27.3.The stock shows a clear positive RSI divergence on Nasdaq Stockholm Small Cap despite a recent breach of the trend floor. With analyst consensus and price targets indicating a significant upside (Redeye 8.50 SEK), we are acting on the technical oversold condition. The setup is perfect for the persona as we expect a quick rebound towards 4.50 SEK driven by short-term covering and upcoming clinical data readouts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
57 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 t sittenHave you seen the news now folks, this must surely be gold that can make the stock rise considerably?·7 t sittenYou must justify why it is a "gold" news because then we haven't read the same news?·7 t sittendo you see that I put a question mark at the end there, I am wondering then if this was good news just to express myself a bit more clearly....
- ·3 päivää sittenAfter a couple of turbulent years in the biotech sector, Cantargia is now in a position where the risk/reward ratio looks unusually attractive. Here are the three supporting pillars of the current bull case: 1. Financial stability and "Proof of Concept" The sale of the CAN10 program to Otsuka Pharmaceutical is the most important event in the company's recent history. It has two crucial effects: Validation: A global player like Otsuka does not buy into the platform without extremely thorough due diligence. This removes a large part of the technical uncertainty surrounding the IL1RAP platform. Cash Runway: With cash reserves extending into 2028, the company is protected against the aggressive, dilutive emissions that otherwise plague the sector. This gives management peace of mind to negotiate from a position of strength. 2. Nadunolimab: Strong data in an "Unmet Need" The main asset, nadunolimab, has delivered convincing results in difficult indications such as pancreatic cancer (PDAC). Data shows an extension of survival (OS) in patients with high IL1RAP expression, which enables a "precision medicine" approach. With FDA’s Fast Track designation, the path to market is shortened, and the company is now facing the crucial pivotal studies. 3. Technical setup and pricing Technically, the stock has consolidated after the falls of recent years. We currently see a positive divergence in RSI, which often indicates that selling pressure is exhausted, and the bottom has been formed. The market capitalization currently primarily reflects the value of the agreement with Otsuka, which means that the market almost prices their oncology pipeline (nadunolimab) at zero. This provides a significant "margin of safety". Conclusion: The big trigger in 2026 will be a potential partnership agreement for nadunolimab. If Cantargia can land an agreement of the same magnitude as CAN10, but for the oncology leg, a significant re-pricing of the stock is set to occur. Remember as always: Biotech requires patience and risk appetite. DYOR.·2 päivää sitten · MuokattuThe many irrelevant small comments - see e.g. below - unfortunately cause important posts like the one above to quickly move down the list and disappear. This absolutely does not do any good for either the stock or the debate. Self-discipline is requested so that this debate page on Shareville does not develop into Facebook, as many other pages have done. If you want to "small-talk" with someone or comment without it being relevant to others, there is a special option on Shareville where you can communicate directly with another person: You can go to the person's profile, look under activity, find a trade, and send a comment below it. This naturally requires that the person has an open portfolio where he/she conducts trades.·2 päivää sittenYes, I can well see that it must be a huge pro lem with the ENORMOUS activity. It's practically once every month that a post appears.
- ·10.4.So I became a shareholder in Cantargia.·8 t sittenPossibility that we move towards 6,- in the near future, but one never knows...it is after all Cantargia.·17 min sittenThat's not how I interpret it. We must wait to hear exactly what they present.
- ·1.4.Do they reach their goals or do they just maintain the projects to get paid?·2 päivää sittenAs usual, only green for a single day, only to then quickly move back towards 4,-.
- ·27.3.The stock shows a clear positive RSI divergence on Nasdaq Stockholm Small Cap despite a recent breach of the trend floor. With analyst consensus and price targets indicating a significant upside (Redeye 8.50 SEK), we are acting on the technical oversold condition. The setup is perfect for the persona as we expect a quick rebound towards 4.50 SEK driven by short-term covering and upcoming clinical data readouts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 581 | - | - | ||
| 496 | - | - | ||
| 771 | - | - | ||
| 415 | - | - | ||
| 72 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 19.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 13.5.2025 | ||
2024 Q4 -tulosraportti 21.2.2025 |
2025 Q4 -tulosraportti
57 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 19.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 13.5.2025 | ||
2024 Q4 -tulosraportti 21.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 t sittenHave you seen the news now folks, this must surely be gold that can make the stock rise considerably?·7 t sittenYou must justify why it is a "gold" news because then we haven't read the same news?·7 t sittendo you see that I put a question mark at the end there, I am wondering then if this was good news just to express myself a bit more clearly....
- ·3 päivää sittenAfter a couple of turbulent years in the biotech sector, Cantargia is now in a position where the risk/reward ratio looks unusually attractive. Here are the three supporting pillars of the current bull case: 1. Financial stability and "Proof of Concept" The sale of the CAN10 program to Otsuka Pharmaceutical is the most important event in the company's recent history. It has two crucial effects: Validation: A global player like Otsuka does not buy into the platform without extremely thorough due diligence. This removes a large part of the technical uncertainty surrounding the IL1RAP platform. Cash Runway: With cash reserves extending into 2028, the company is protected against the aggressive, dilutive emissions that otherwise plague the sector. This gives management peace of mind to negotiate from a position of strength. 2. Nadunolimab: Strong data in an "Unmet Need" The main asset, nadunolimab, has delivered convincing results in difficult indications such as pancreatic cancer (PDAC). Data shows an extension of survival (OS) in patients with high IL1RAP expression, which enables a "precision medicine" approach. With FDA’s Fast Track designation, the path to market is shortened, and the company is now facing the crucial pivotal studies. 3. Technical setup and pricing Technically, the stock has consolidated after the falls of recent years. We currently see a positive divergence in RSI, which often indicates that selling pressure is exhausted, and the bottom has been formed. The market capitalization currently primarily reflects the value of the agreement with Otsuka, which means that the market almost prices their oncology pipeline (nadunolimab) at zero. This provides a significant "margin of safety". Conclusion: The big trigger in 2026 will be a potential partnership agreement for nadunolimab. If Cantargia can land an agreement of the same magnitude as CAN10, but for the oncology leg, a significant re-pricing of the stock is set to occur. Remember as always: Biotech requires patience and risk appetite. DYOR.·2 päivää sitten · MuokattuThe many irrelevant small comments - see e.g. below - unfortunately cause important posts like the one above to quickly move down the list and disappear. This absolutely does not do any good for either the stock or the debate. Self-discipline is requested so that this debate page on Shareville does not develop into Facebook, as many other pages have done. If you want to "small-talk" with someone or comment without it being relevant to others, there is a special option on Shareville where you can communicate directly with another person: You can go to the person's profile, look under activity, find a trade, and send a comment below it. This naturally requires that the person has an open portfolio where he/she conducts trades.·2 päivää sittenYes, I can well see that it must be a huge pro lem with the ENORMOUS activity. It's practically once every month that a post appears.
- ·10.4.So I became a shareholder in Cantargia.·8 t sittenPossibility that we move towards 6,- in the near future, but one never knows...it is after all Cantargia.·17 min sittenThat's not how I interpret it. We must wait to hear exactly what they present.
- ·1.4.Do they reach their goals or do they just maintain the projects to get paid?·2 päivää sittenAs usual, only green for a single day, only to then quickly move back towards 4,-.
- ·27.3.The stock shows a clear positive RSI divergence on Nasdaq Stockholm Small Cap despite a recent breach of the trend floor. With analyst consensus and price targets indicating a significant upside (Redeye 8.50 SEK), we are acting on the technical oversold condition. The setup is perfect for the persona as we expect a quick rebound towards 4.50 SEK driven by short-term covering and upcoming clinical data readouts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 581 | - | - | ||
| 496 | - | - | ||
| 771 | - | - | ||
| 415 | - | - | ||
| 72 | - | - |
Välittäjätilasto
Dataa ei löytynyt